Valérie Ugo

Has grant

Hematologie biologique, Prof. MD, PhD

Université d'Angers

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Valérie Ugo is a Professor of Biological Hematology at CHU Angers in France. Her research focuses on the molecular alterations in myeloproliferative neoplasms, including primary myelofibrosis and essential thrombocythemia, as well as the impact of comorbidities on chemotherapy outcomes in older patients with acute myeloid leukemia. She has contributed to various studies exploring genetic mutations and their association with thrombocytosis and thrombosis risk stratification.

Recent Grants

Grant: Open

FIMBANK : Base clinico-biologique nationale des syndromes myéloprolifératifs

Open Date: 2022-01-01

Close Date: 2026-12-01

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Damien Luque Paz

FRANCE

View details

Simona Pagliuca

FRANCE

View details

Jérémie Riou

Associate Professor

INSERM U1065

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Valérie Ugo

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis

Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis.

CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.

Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores.

Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.

JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes.

Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis

Different number of circulating CD34 + cells in essential thrombocythemia, prefibrotic/early primary myelofibrosis, and overt primary myelofibrosis.

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.

Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations.

Collaborators (3)

Damien Luque Paz

Simona Pagliuca

Jérémie Riou

Make your next move.